ArticleResearch square2026
Structural and biochemical insight into allosteric regulation of the human 2-aminoadipic semialdehyde synthase, a bifunctional enzyme involved in lysine catabolism.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Multiple clinically significant inborn errors of metabolism occur in the lysine degradation, even so the regulation of this biochemical pathway remains understudied. The initial rate-limiting step of lysine catabolism is catalyzed by the bifunctional enzyme 2-aminoadipic semialdehyde synthase (AASS). Therefore, understanding the regulation of AASS activity in normal and disease states will be critical for developing novel therapeutic approaches that modulate lysine degradation flux. Here, we report the cryo-EM structure of the full-length 400 kDa tetrameric AASS enzyme complex with substrates and products bound to both the lysine-2-oxoglutarate (LOR) and saccharopine dehydrogenase (SDH) catalytic domains. Our full-length structure shows that two SDH dimers are connected by a long alpha-helix group and flexible loops to a core LOR tetramer. This functional arrangement gives the SDH domain flexibility to move and readily access the products from the LOR domain. Through chemical screens, we also identified allosteric compounds that modulate activity of the AASS. Maleimides, a class of Michael-Addition chemistry substrates, activate the enzyme by reacting with cysteine 414 and shifting the pH optimum for biochemical activity. This observation can be explained mechanistically by pronounced changes in the affinity for NADPH as a function of pH. Remarkably, the mutagenesis of this allosteric Cys414 has dramatic effects on the enzyme's conformation and activity despite being more than 12 Å from the active site. Simulations also show how changes at this distal site can affect the dynamics of the enzyme. Another compound, 1-methylnicotinamide, inhibits the enzyme by catalyzing the formation of a disulfide bond, which was observed through cryo-EM structural studies. Combined, our data indicate that AASS can be modulated at multiple allosteric sites through small molecules providing opportunities to regulate lysine catabolism by either inhibition or activation. Moreover, small changes near the hinge of an enzyme can have large effects on the catalytic properties of the enzyme. Lastly, targeting allosteric cysteines may be a general strategy for modulating enzyme activity by altering the dynamics of the enzyme.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.